500 Boylston Street
48 articles with Vedanta Biosciences
Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients Award is first-ever by BARDA directed to advance development of a microbiome drug CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Vedanta Biosciences , a clinical-stage company developing a new category of therapies for immune-mediated di
Veteran IP attorney Nancy Chiu Wilker, Ph.D., J.D., joins leadership team as vice president of legal Company also secured $15 million from Oxford Finance to further support pipeline development
Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)
VE202 was generally safe and well-tolerated in healthy volunteers, with durable and dose-dependent colonization that will inform the Phase 2 dose regimen
Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb's Opdivo® (Nivolumab)
First clinical study of a rationally-defined bacterial consortium (VE800) for the treatment of cancer
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
Vedanta Biosciences eligible for an additional $3.5 million upon completion of certain milestones
Vedanta’s VE707 microbiome program, which is still in the preclinical stage, is designed to restore healthy microbiota and prevent infection and colonization recurrence by multi-drug-resistant superbugs.
Vedanta Biosciences, a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced that Silvia Caballero, Ph.D., who leads Vedanta’s program on multidrug-resistant organisms (MDRO), has been named to the TIME 100 NEXT list.
BioSpace takes a look at some of the financing rounds announced over the past few weeks.
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, is pleased to announce that its co-founder and CEO Bernat Olle, Ph.D., received the 2019 Barry M. Portnoy Immigrant Entrepreneur Award from The Immigrant Learning Center in the Life Science Business category.
Vedanta Biosciences, announced a $16.6 million Series C-2 financing round, bringing the total capital raised in its Series C and C-2 round to $62.1 million.
PureTech Affiliate Vedanta Biosciences Raises Additional $16.6 Million of Series C Financing, Bringing Total Capital Raised to $62.1 Million
PureTech Health plc (LSE: PRTC) (“PureTech”), a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, is pleased to note that its affiliate, Vedanta Biosciences, added $16.6 million to its Series C financing round, bringing the total capital raised to $62.1 million.
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy
Vedanta Biosciences’ Silvia Caballero, Ph.D., Named as an MIT Technology Review Global Innovator Under 35
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that a Vedanta scientific team member, Silvia Caballero, Ph.D., has been named as one of MIT Technology Review’s Global Innovators Under 35.
Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week
Vedanta Biosciences, today announced the presentation of expanded, long-term positive data from its Phase 1a/1b study of VE303, the Company’s lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI).
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
PureTech Health plc announced that its affiliates Gelesis and Vedanta Biosciences will deliver poster presentations of clinical data at Digestive Disease Week, the world’s largest gathering of physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
$18.5 million in extension funding will support clinical pipeline of microbiome-derived product candidates
Upheld patent EP2575835 covers therapeutic compositions of clostridial bacterial species derived from the human microbiome
Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors
Research also identified a rationally-defined consortium of human commensal bacteria (VE800) that robustly induces IFNy+ CD8+ T cells and enhances antitumor immunity
Vedanta Biosciences Raises $27 Million Series C Financing to Advance Clinical Pipeline of Microbiome-Derived Product Candidates
Participants include the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure, and PureTech Health